Sanofi's Dr Jack Prior detailed a data maturity framework for biologics manufacturing, while FDA and Gilead panelists debated risk-based AI validation.
|Articles|November 4, 2020
Sanofi Wins ISPE FOYA Overall Award
Sanofi’s Digitally Enabled Integrated Continuous Biomanufacturing Facility in Framingham, MA was named the Overall Award winner at the ISPE virtual annual meeting.
Advertisement
Sanofi was named the 2020 Facility of the Year Awards (FOYA) Overall Award winner by the International Society for Pharmaceutical Engineering (ISPE) at ISPE’s virtual awards banquet at the virtual annual meeting, the organization announced in a Nov. 3, 2020 press release. In April 2020, Sanofi received the Facility of the Future Category Award for its Digitally Enabled Integrated Continuous Biomanufacturing Facility in Framingham, MA. The facility’s continuous upstream and downstream processing design incorporates lean operations principles, and the facility design and the use of disposable process technology enables flexibility. Digital integration is extensive; the entire facility is run using a comprehensive suite of digital solutions.
According to the press release, achieving higher capacity in a smaller footprint provides the basis for an improved environmental footprint with:
- More than 90% reduction in chemical usage per year
- More than 90% reduction in water usage per year
- 80% reduction in energy consumption and carbon dioxide emissions per year
- More than 320 tons of waste saved from landfills every year.
Source:
Advertisement
Related to this article
Tambotatug pelitecan (Tam-Peli), a B7-H3-targeted antibody-drug conjugate, is the second of at least three B7-H3-targeted ADCs to post positive late-stage data in relapsed small-cell lung cancer this year.
Aptar Pharma's Nanopharm business will lead inhaled formulation development and device assessment for ACT-101, Aceso Therapeutics' antisense oligonucleotide candidate designed to correct CFTR protein function in cystic fibrosis patients carrying the F508del mutation.
Athenecia Faggins of Minaris Advanced Therapies discusses raw material qualification, supplier management, testing, and risk control for advanced therapy manufacturing.
Four cell therapy developers have pulled back from ex vivo manufacturing in the past month — ArsenalBio, TScan Therapeutics, and Cellectis all pivoted to in vivo approaches, while Bristol Myers Squibb terminated its manufacturing partnership with automation specialist Cellares after determining its platform couldn't meet requirements for commercial Breyanzi production, triggering layoffs.
Samsung Biologics signed a $262 million contract manufacturing agreement with an undisclosed European pharmaceutical company, extending production commitments through 2033 and lifting the CDMO's cumulative contract value past $21.9 billion.
CordenPharma is expanding its Caponago, Italy site with a €80 million multi-year investment and new aseptic fill-finish lines, aiming to reach 500 million sterile injectable units of annual capacity to meet rising demand across peptide, biologic, LNP, and oligonucleotide-based drug products.
Solstice Oncology launched with a $225 million Series A financing to advance porustobart, a second-generation, Fc-enhanced CTLA-4 antibody licensed from Harbour BioMed, into neoadjuvant Phase 2 testing for microsatellite-stable colon cancer.
Advertisement
Advertisement